BIOSTOCK: The future of obesity treatment – Iconovo develops intranasal semaglutide

/in /by

This morning, BIOSTOCK released an article regarding Iconovo’s development of an intranasal semaglutide formulation for the treatment of obesity in the ICOone Nasal platform. Please read and you will get more insights to how we have laid out our plans.

To learn more, please follow the link to get the full story.